David R. Bauer

Davis Polk advised the underwriters and the joint global coordinators in the public offering of BeiGene, Ltd. on the Hong Kong Stock Exchange. The gross proceeds from the offering…

Davis Polk advised AC Immune SA in connection with its $117.5 million U.S. follow-on public offering. AC Immune sold 8,500,000 of its newly issued common shares and subscription rights…

Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public offering of common stock of Constellation Pharmaceuticals, Inc. The…

Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of CytomX Therapeutics, Inc. The shares are listed on the NASDAQ…

Davis Polk advised Entera Bio Ltd. on its initial public offering of 1,400,000 ordinary shares and 1,400,000 warrants to purchase up to 700,000 ordinary shares. In addition, Entera Bio Ltd…

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 7,035,000 shares of common stock of Forty Seven, Inc. Forty Seven’s…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100 million initial public offering of common stock of Magenta…

Davis Polk advised the underwriters in connection with an initial public offering of 7,359,998 shares of common stock of Aptinyx Inc., at $16.00 per share (which includes the exercise in…

Davis Polk is advising Roche on its acquisition of the outstanding shares of Foundation Medicine, Inc. not already owned by Roche at a price of $137.00 per share in cash. The transaction is…

Davis Polk advised Kadmon Holdings, Inc. in connection with a $113.2 million offering of 32,022,728 shares of common stock, which included the full exercise of the underwriters’ option to…